SUGAR LAND--August 7, 2015--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--If at first you don't succeed, try, try again. When it comes to merger and acquisition (M&A) action to aid in its pursuit of growth, Israeli generic giant Teva (NYSE:TEVA) (Petah Tikva, Israel) has done just that. After having its $40 billion unsolicited buy offer in early 2015 spurned by smaller generic maker Mylan (NASDAQ:MYL) (Canonsburg, Pennsylvania), Teva upped the ante to $40.5 billion to win the generic division of Botox king Allergan plc (NYSE:AGN) (Dublin, Ireland).

Within this article: How M&A activity is affecting the booming market for generics

Other companies featured: Novartis AG (NYSE:NVS)

Login to Read More